Antipsychotics: market growth to tail off

Published By Datamonitor

Antipsychotics: new classes dominate early stage development

Published By Datamonitor

Antipsychotics: new classes to make an impact

Published By Datamonitor

Antipsychotics: pharmaceutical companies control late stage R&D

Published By Datamonitor

Antipsychotics: sales up $2 billion by 2008

Published By Datamonitor

Anxiety disorders: global sales set to slide

Published By Datamonitor

Anxiety: a day to raise awareness - and drug revenues

Published By Datamonitor

APA 2010: Alkermes prepares to enter potentially lucrative opioid dependence market

At this year's American Psychiatric Association meeting, US pharmaceutical company Alkermes presented promising new data for Vivitrol in the treatment of opioid dependence. The FDA is currently assessing the drug under a priority review, and approval in the burgeoning opioid dependence indication would be a major boon for Alkermes.

Published By Datamonitor

APA 2010: limited data highlight unmet needs in bipolar disorder

Several leading drug makers presented new data in bipolar disorder at this year's meeting of the American Psychiatric Association. Despite Cephalon's Nuvigil showing promise as an adjunct, modest data for antipsychotics from Merck & Co and Pfizer served only to highlight the remaining unmet needs in the treatment of this disease.

Published By Datamonitor

APA 2010: Merck and Dainippon take center stage to present new schizophrenia therapies

Schizophrenia played a prominent role at this year's American Psychiatric Association Annual Meeting due to the prevailing high level of unmet need. Merck & Co and Dainippon Sumitomo presented data for new drugs which Datamonitor believes represent important additions to the current treatment portfolio. Elsewhere, an interesting lecture predicted a future of personalized schizophrenia treatments.

Published By Datamonitor